Skip to content
Apogee Biotechnology Corporation

Apogee Biotechnology Corporation

  • Welcome
  • News
  • Technology
  • Lead Compound
  • Contact Us / Policies

Phase 2/3 Study with opaganib approved in UK for COVID-19

Posted bylwm100 July 21, 2020July 21, 2020 Leave a comment on Phase 2/3 Study with opaganib approved in UK for COVID-19

https://www.redhillbio.com/RedHill/Templates/showpage.asp?DBID=1&LNGID=1&TMID=178&FID=2432&PID=0&IID=16270

Posted bylwm100July 21, 2020July 21, 2020Posted inUncategorized

Post navigation

Previous Post Previous post:
Phase 2/3 Clinical Trial with Opaganib for COVID-19 Submitted
Next Post Next post:
Phase 2/3 study with opaganib approved in Russia for COVID-19; United States trial rapidly enrolling

Leave a comment

Cancel reply

Your email address will not be published. Required fields are marked *

Apogee Biotechnology Corporation, Proudly powered by WordPress.